Citations

Background TAR DNA-binding protein 43 (TDP-43) proteinopathy contributes to Alzheimer's disease progression, but diagnosis remains autopsy-dependent. Objective This study aimed to develop a predictive model using FDG-PET imaging to identify brain regions associated with TDP-43 pathology in vivo. Methods Penalized logistic regression analyzed data from 294 participants and a subset of 159 with Braak and Thal ≥4. Features included FDG standard uptake value ratios (SUVRs) from 123 brain regions and age. Participants were split into training (90%) and testing (10%) datasets, with significant predictors identified by non-zero coefficients at optimal lambda. Results The model achieved 68% accuracy (AUC = 0.70) in 294 participants, highlighting the middle temporal gyrus, parahippocampal gyrus, and hippocampus. In the subset (n = 159), accuracy was 65% (AUC = 0.71), with the medial amygdala and precentral gyrus as key predictors of TDP-43 pathology. Conclusions This study suggests a moderate predictive accuracy of FDG-PET to identify brain regions associated with Alzheimer's disease-related TDP-43 proteinopathy.

Abstract Background Atypical clinical presentations of Alzheimer's disease (AD) are associated with heterogeneous patterns of cortical tau‐PET uptake. The medial‐temporal (MTL) meta‐ROI is typically used to determine tau‐PET abnormality in AD, but this approach may not detect focal uptake in atypical patients. Our goal was to develop regional tau‐PET cut‐points and determine whether the number of positive regions better captures positive tau‐PET signal in atypical AD. Method 127 amyloid‐positive atypical AD (visual=68, language=39, motor=15, others=5) and 62 amyloid‐negative cognitively unimpaired (CU) individuals were recruited by the Neurodegenerative Research Group, Mayo Clinic, and underwent, amyloid‐PET and 18 F‐AV‐1451(tau)‐PET. Images were parcellated using the modified Harvard‐Oxford atlas and we focused on 67 AD‐specific regions. Rather than using the average SUVR across voxels within a region to quantify uptake, we used the 95 th percentile of SUVR values across voxels within a region to capture focal cases. We then used receiver operating characteristic (ROC) methods and a Youden threshold to define regional abnormality. The number of abnormal regions was calculated for each participant and used to discriminate between CU and atypical AD at the individual level. Result Across 64 regions, our approach showed excellent (AUROC>0.90) differentiation between atypical AD and CU. The temporal‐fusiform, parahippocampal gyrus and inferior temporal gyrus showed the best differentiation (Figure 1). All 67 regions showed excellent specificity (>85%), with 63 regions showing excellent sensitivity (≥80%). The lateral occipital cortex, temporal‐fusiform and parahippocampal gyrus showed the best specificity and sensitivity (Figure 2). The distribution of the number of tau‐elevated regions is shown in Figure 3. 74% of CU had no positive regions, while 43% of the atypical AD patients had all 67 regions affected. An optimal threshold of 7 tau‐elevated regions classified all CU below, and 123 (97%) atypical AD above threshold. Using a standard approach based on the average SUVR in the MTL meta‐ROI, only 116 (91%) atypical AD patients were tau‐PET positive. Conclusion Tau uptake in temporal regions showed the greatest group‐level differentiation. However, examining regional tau‐positivity may offer better sensitivity in atypical AD patients compared to the temporal meta‐ROI, likely due to the presence of focal non‐temporal patterns of uptake.

Abstract Background Plasma neurofilament light chains (NfL) and glial fibrillary acidic protein (GFAP) are blood‐based biomarkers of axonal injury and astrocytic activation, respectively, that are elevated in those with Alzheimer's disease (AD) and mild cognitive impairment (MCI) relative to cognitively unimpaired (CU) individuals. Neurite orientation dispersion and density imaging (NODDI) is a multishell diffusion MRI method capable of evaluating tissue microstructure at the axonal and dendritic level. We evaluated associations between temporal cortex orientation dispersion index (ODI), neurite density index (NDI) and isotropic volume fraction (ISOVF) and plasma NfL and GFAP concentrations. Method We included Mayo Clinic Study of Aging (MCSA) participants (ages 60‐95 years) with diagnoses or CU ( n = 356) or MCI ( n = 60), and Alzheimer's Dementia Research Center (ADRC) participants with dementia ( n = 51). NODDI imaging was obtained on a 3T Siemens Prisma scanner with 2 mm isotropic resolution. NfL and GFAP were measured using the Simoa® Neurology 4‐Plex E Advantage kit. We fit separate linear regression models within each MCALT_ADIR122 cortical ROI with regional NODDI as the primary predictor and log‐transformed plasma concentration as the outcome. Models were adjusted for age, sex, BMI, cortical thickness (or hippocampal & amygdalar volume) and total intracranial volume. Result The Table displays demographic data. Figures 1 and 2 show the relationship of NDI and ISOVF measures to plasma NfL concentrations across participants in individual ROIs (similar findings were noted with GFAP). A significant inverse relationship between NfL concentrations and NDI was observed in hippocampus, amygdala, entorhinal cortex, parahippocampal gyrus as well as all temporal neocortical regions except the superior temporal gyrus ( p <0.001) (Figure 1), whereas higher NfL concentrations were associated with higher ISOVF in all regions ( p <0.001) (Figure 2). Fewer significant associations were also seen with ODI. After adjusting for age, cortical thickness/volume and other confounds, significant associations with NDI remain, particularly in hippocampal and amygdalar regions. Conclusion NODDI‐derived measures (NDI and ISOVF) within the temporal lobe cortical regions demonstrate significant associations with plasma biomarkers of axonal and astrocytic dysfunction that are elevated during cognitive decline. This association provides preliminary validation of the utility of NODDI in assessing cortical microstructural changes associated with cognitive decline.

Abstract Background Chronic kidney disease (CKD) is associated with increased blood‐based biomarker concentrations, potentially confounding their utility in Alzheimer's disease (AD) evaluation. While plasma phosphorylated tau217 ( p ‐tau217) is elevated in the presence of amyloid related pathology, amyloid beta 1‐42 (Aβ42) is decreased. We investigated the association of plasma p ‐tau217, non‐phosphorylated tau217 (np‐tau217), Aβ42, Aβ40, as well as the Aβ42/Aβ40 and p ‐tau217/Aβ42 ratios, versus decreased estimated glomerular filtration rate (eGFR in mL/min/1.73 m 2 ) in individuals without amyloid pathology. Method This study included participants with CKD stages 1‐2 (eGFR 60‐98, n = 50), and stages 3‐4 (eGFR 25‐59, n = 33), who were Pittsburgh 11 C‐Compound B amyloid‐PET negative (Centiloid of < 25). Plasma p ‐tau217, np‐tau217, Aβ42, and Aβ40 were measured by immunoprecipitation mass spectrometry (C 2 N Diagnostics). %p‐tau217 [( p ‐tau217/np‐tau217) x100], Aβ42/Aβ40 ratio, and p ‐tau217/Aβ42 ratio were calculated. Log‐Log (power function) best‐fit regression analysis was used to quantitatively predict effects of changes in eGFR (2021 CKD‐EPI equation) versus each single analyte or ratio (Figure 1). Result Selected best‐fit analyte equations versus eGFR are shown in Table 1. The predicted percent increase of p ‐tau217 as eGFR decreases from 60 to 45 was 52% (95% CI: 30–78%). Significantly smaller increases of 16% were predicted for Aβ42 (95% CI: 12–21%), and 19% for Aβ40 (95% CI: 16–23%) over the same eGFR range. The best‐fit predicted increase for the p ‐tau217/Aβ42 ratio and %p‐tau217 as eGFR decreases from 60 to 45 was 31% (95% CI: 12–53%), and 19% (95% CI: 2–38%), respectively. While not recommended for assessment of amyloid pathology, the Aβ42/Aβ40 ratio did not exhibit a predicted increase (‐2.3% decrease, 95% CI: ‐5.2–0.6%) versus decreasing eGFR from 60 to 45. Conclusion The use of either %p‐tau217 or the p ‐tau217/Aβ42 ratio (to a lesser degree) reduced the confounding effects of decreasing eGFR as compared to p ‐tau217 alone. Aβ42 and Aβ40 exhibited similar reduced predicted increases versus decreasing eGFR as compared to p ‐tau217. Relative to the predicted effects of decreasing eGFR on p ‐tau217 measurements, the p ‐tau217/Aβ42 ratio relative increase was reduced by 40%, while the relative increase was reduced by 63% for %p‐tau217 measurements.

Abstract Background Plasma neurofilament light chains (NfL) and glial fibrillary acidic protein (GFAP) are blood‐based biomarkers of axonal injury and astrocytic activation, respectively, that are elevated in those with Alzheimer’s disease (AD) and mild cognitive impairment (MCI) relative to cognitively unimpaired (CU) individuals. Neurite orientation dispersion and density imaging (NODDI) is a multishell diffusion MRI method capable of evaluating tissue microstructure at the axonal and dendritic level. We evaluated associations between temporal cortex orientation dispersion index (ODI), neurite density index (NDI) and isotropic volume fraction (ISOVF) and plasma NfL and GFAP concentrations. Method We included Mayo Clinic Study of Aging (MCSA) participants (ages 60‐95 years) with diagnoses or CU ( n = 356) or MCI ( n = 60), and Alzheimer’s Dementia Research Center (ADRC) participants with dementia ( n = 51). NODDI imaging was obtained on a 3T Siemens Prisma scanner with 2 mm isotropic resolution. NfL and GFAP were measured using the Simoa® Neurology 4‐Plex E Advantage kit. We fit separate linear regression models within each MCALT_ADIR122 cortical ROI with regional NODDI as the primary predictor and log‐transformed plasma concentration as the outcome. Models were adjusted for age, sex, BMI, cortical thickness (or hippocampal & amygdalar volume) and total intracranial volume. Result The Table displays demographic data. Figures 1 & 2 show the relationship of NDI and ISOVF measures to plasma NfL concentrations across participants in individual ROIs (similar findings were noted with GFAP). A significant inverse relationship between NfL concentrations and NDI was observed in hippocampus, amygdala, entorhinal cortex, parahippocampal gyrus as well as all temporal neocortical regions except the superior temporal gyrus ( p <0.001) (Figure 1), whereas higher NfL concentrations were associated with higher ISOVF in all regions ( p <0.001) (Figure 2). Fewer significant associations were also seen with ODI. After adjusting for age, cortical thickness/volume and other confounds, significant associations with NDI remain, particularly in hippocampal and amygdalar regions. Conclusion NODDI‐derived measures (NDI and ISOVF) within the temporal lobe cortical regions demonstrate significant associations with plasma biomarkers of axonal and astrocytic dysfunction that are elevated during cognitive decline. This association provides preliminary validation of the utility of NODDI in assessing cortical microstructural changes associated with cognitive decline.

Abstract Objective: We investigated differences in cognition between variants of progressive supranuclear palsy (PSP) including PSP-Richardson (PSP-RS) and subcortical and cortical variants using updated diagnostic criteria and comprehensive neuropsychological assessment. Method: We recruited 140 participants with PSP (age = 71.3 ± 6.9 years; education = 15.0 ± 2.8 years; 49.3% female) who completed neurological and neuropsychological assessment. Participants received diagnoses of PSP clinical variants at their evaluation (or retrospectively if evaluated before 2017) according to the Movement Disorder Society PSP criteria. We grouped variants as PSP-RS (62 participants), PSP-Cortical (25 with PSP-speech/language and 9 with PSP-corticobasal syndrome), and PSP-Subcortical (27 with PSP-parkinsonism, 11 with PSP-progressive gait freezing, and 6 with PSP-postural instability). Analysis of covariance adjusted for age assessed for differences in neuropsychological performance between variants across cognitive domains. Results: PSP-Cortical participants performed worst on measures of visual attention/working memory (Spatial Span Forward/Backward/Total), executive function (Frontal Assessment Battery), and language (Letter Fluency). PSP-RS participants performed worst on verbal memory (Camden Words). There were no significant group differences for the MoCA or indices of visuospatial function. There were no sex or education differences between PSP groups; however, there were differences in age at visit and disease duration. Conclusions: In a large sample of participants with PSP, there were differences in cognition across PSP-RS, PSP-Subcortical, and PSP-Cortical variants, with PSP-Cortical and, to a lesser extent, PSP-RS, performing worse on tests of attention and executive function. These findings suggest cognitive distinctions among PSP clinical variants and highlight the value of neuropsychological assessment in differential diagnosis of PSP subtypes for more accurate and timely clinical classification.

Abstract INTRODUCTION When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid‐beta‐peptide (Aβ) related pathology are discordant, therapeutic decision‐making becomes uncertain. METHODS Using data from patients with mild cognitive impairment ( n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints. RESULTS Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures. DISCUSSION In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline. Highlights Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI). CSF‐PET discrepant persons with MCI tend to have less abnormal values initially. CSF‐PET discrepant persons with MCI have a benign prognosis at 4 years.

Abstract INTRODUCTION Temporal cortical microstructural changes precede cortical atrophy during memory decline. We used neurite orientation dispersion and density imaging (NODDI) to assess such early microstructural change. METHODS Cognitively unimpaired (CU, n = 725) and mildly cognitively impaired (MCI, n = 111) participants from the Mayo Clinic Study of Aging underwent 3T magnetic resonance imaging (MRI), including NODDI and neuropsychological evaluation for calculation of memory z scores. Linear mixed effects modelling assessed the relationship between temporal cortical Neurite Density Index (NDI), Orientation Dispersion Index (ODI), and both baseline and mean annual change in memory z scores. RESULTS NDI was significantly associated with both baseline memory z scores and mean annual change of memory z scores, in the hippocampi and amygdalae. Similar significant associations with ODI were seen in hippocampi, parahippocampal, and fusiform gyri. DISCUSSION Temporal cortical NDI and ODI are early imaging biomarkers of cortical microstructural integrity that may predict memory decline in CU and MCI individuals. Highlights We imaged 836 participants in the Mayo Clinic Study of Aging, who were either cognitively unimpaired (CU) or suffered from mild cognitive impairment (MCI). Neurite orientation dispersion and density imaging (NODDI) is an advanced diffusion magnetic resonance imaging (MRI) technique We found significant associations between new NODDI imaging biomarkers of microstructural integrity and memory function in CU and MCI individuals These relationships were both cross‐sectional in nature and associated with future memory decline Future application of NODDI imaging biomarkers in the setting of anti‐amyloid monoclonal antibody therapy may provide greater insight into memory decline than current cortical atrophy measures.